非酒精性脂肪性肝炎防治新思路

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)主要包括非酒精性脂肪肝(NAFL)和非酒精性脂肪性肝炎(NASH)。随着患病率的逐年上升,越来越多的试验研究了NAFL及相关疾病的治疗和预防方法,但仍没有经批准的绝对有效的措施,目前的治疗方法各有优劣,因此对该病的预防显得尤为重要。本文对NASH的最新防治措施进行讨论,为进一步减缓疾病进展提供参考。

关键词: 非酒精性脂肪性肝炎, 减重, 胰岛素抵抗, 治疗方式

尚敏, 陈平, 金志健, 张铭麟, 王珏, 侯叶廷. 非酒精性脂肪性肝炎防治新思路[J]. 肝脏, 2024, 29(10): 1289-1291.

/ 推荐

[1] Loomba R, Adams L A. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH[J]. Hepatology,2019,70:1885-1888.
[2] Younossi Z M. Non-alcoholic fatty liver disease-a global public health perspective[J]. Hepatology,2019,70:531-544.
[3] Estes C, Anstee Q M, Arias-Loste M T, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016－2030[J]. Hepatology,2018,69:896-904.
[4] Watanabe M, Tozzi R, Risi R, et al. Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease: a comprehensive review of the literature[J]. Obes Rev,2020,21(8): 13-24.
[5] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. Diabetologia,2016,59(6):1121-1140.
[6] Gepner Y, Shelef I, Schwarzfuchs D, et al. Effect of distinct lifestyle interventions on mobilization of fat storage pools: CENTRAL magnetic resonance imaging randomized controlled trial[J]. Circulation,2018,137(11):1143-1157.
[7] Meir A Y, Rinott E,Tsaban G,et al. Effect of green- Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial[J]. Gut,2021,70(11):2085-2095.
[8] Properzi C, O'Sullivan T A, Sherriff J L, et al. Ad libitum mediterranean and low-Fat diets both significantly reduce hepatic steatosis: a randomized controlled trial[J]. Hepatology,2018,68(5):1741-1754.
[9] Shang F, Li X, Jiang X. Coffee consumption and risk of the metabolic syndrome: a meta-analysis[J]. Diabetes Metab,2016,42(2):80-87.
[10] Abdelmalek M F, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease[J]. Hepatology,2010,51:1961-1971.
[11] Koopman K E, Caan M W, Nederveen A J, et al. Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: a randomized controlled trial[J]. Hepatology,2014,60:545-553.
[12] Babu A F, Csader S, Lok J, et al. Positive effects of exercise intervention without weight loss and dietary changes in NAFLD-related clinical parameters: a systematic review and meta-analysis[J]. Nutrients,2021,13(9):31-35.
[13] Zhang H J, He J, Pan L L, et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial[J]. JAMA Intern Med,2016,176(8):1074-1082.
[14] Hashida R, Kawaguchi T, Bekki M, et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review[J]. Hepatol,2017,66:142-152.
[15] Hatami M, Eftekhari E. The effect of combined aerobic and resistance training on hepatic enzymes in males with nonalcoholic fatty liver[J]. Biotechnol,2016,3:25-29.
[16] Wei H, Qu H, Wang H, et al. Associations between sitting time and non-alcoholic fatty liver diseases in Chinese male workers: a cross-sectional study[J]. BMJ Open,2016,6:e011939.
[17] Seo Y, Sung G H, Lee S, et al. Weekend catch-up sleep is associated with the alleviation of non-alcoholic fatty liver disease[J]. Annals of Hepatology,2022,27:1006-1009.
[18] Liu X, Baecker A, Wu M, et al. Interaction between tobacco smoking and hepatitis B virus infection on the risk of liver cancer in a Chinese population[J]. Cancer,2018,142:1560-1567.
[19] Charatcharoenwitthaya P, Karaketklang K, Aekplakorn W. Cigarette smoking increased risk of overall mortality in patients with non-alcoholic fatty liver disease: a nationwide population-based cohort study[J]. Front Med,2020,7:49-60.
[20] Blomdahl J, Nasr P, Ekstedt M, et al. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus[J]. Metabolism Clinical and Experimental, 2021,115:154439.
[21] Pan C S, Stanley T L. Effect of weight loss medications on hepatic steatosis and steatohepatitis: a systematic review[J]. Front Endocrinol (Lausanne),2020,21,11:68-70.
[22] Petroni M L, Brodosi L, Bugianesi E, et al. Management of non-alcoholic fatty liver disease[J]. BMJ,2021,372:48-47.
[23] Sanyal A J, Chalasani N, Kowdley K V, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. NEJM,2010,362(18):1675-1685.
[24] Nadinskaia M, Maevskaya M, Ivashkin V, et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease[J]. World J Gastroenterol,2021,27(10):959-975.
[25] Eslamparast T, Poustchi H, Zamani F, et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study[J]. Am J Clin Nutr,2014,99(3):535-542.
[26] Wong V W, Wong G L, Chan R S, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease[J]. Hepatol,2018,69(6):1349-1356.
[27] Lassailly G, Caiazzo R, Ntandja-Wandji L-C, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis[J]. Gastroenterology,2020,159(4):1290-1301.
[28] Gasoyan H, Tajeu G, Halpern M T, et al. Reasons for underutilization of bariatric surgery: The role of insurance benefit design[J]. Surg Obes Relat Dis,2019,15(1):146-151.
[29] Brunaldi V O, Neto M G. Endoscopic procedures for weight loss[J]. Curr Obes Rep,2021 ,10(3):290-300.
[30] Chandan S, Mohan B P, Khan S R, et al. Efficacy and safety of intragastric balloon (IGB) in non-alcoholic fatty liver disease (NAFLD): a Comprehensive review and meta-analysis[J]. Obes Surg,2021,31(3):1271-1279.
[31] Hajifathalian K, Mehta A, Ang B, et al. Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty[J]. Gastrointest Endosc,2021,93(5):1110-1118.
[32] Roehlen N, Laubner K, Bettinger D, et al. Duodenal-jejunal bypass liner (DJBL) improves cardiovascular risk biomarkers and predicted 4-year risk of major cv events in patients with type 2 diabetes and metabolic syndrome[J]. Obes Surg,2020,30(4):1200-1210.
[33] de Jonge C, Fuentes S, Zoetendal E G, et al. Metabolic improvement in obese patients after duodenal-jejunal exclusion is associated with intestinal microbiota composition changes[J]. Int J Obes (Lond),2019 ,43(12):2509-2517.

非酒精性脂肪性肝炎防治新思路

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张心怡, 贺娜, 张粉娜, 孙荣荣, 王梓依, 郝帅, 王辉, 边娜娜, 闫红林. 丙型肝炎病毒感染合并2型糖尿病的相关研究进展[J]. 肝脏, 2024, 29(3): 355-357.
[2]	李卫侠, 陈克敏. MRI成像技术在非酒精性脂肪性肝病患者肝脏评估中的作用[J]. 肝脏, 2024, 29(2): 154-156.
[3]	洪文文, 张若梅, 谭善忠. 细胞焦亡与代谢相关脂肪性肝病发展的相关性及治疗机制研究进展[J]. 肝脏, 2024, 29(2): 235-240.
[4]	吴雯玥, 孙亚朦, 尤红. 肝纤维化逆转:小进步尚待大突破[J]. 肝脏, 2024, 29(1): 13-15.
[5]	栗雯霏, 张捷, 栗建辉. 影像技术对非酒精性脂肪肝的评价[J]. 肝脏, 2023, 28(7): 875-880.
[6]	杨英豪, 司梁燕, 梁栋. 慢性丙型肝炎合并代谢相关脂肪性肝病研究现状[J]. 肝脏, 2023, 28(6): 727-730.
[7]	厉绾, 韩艳霞, 谢寿珍, 马颖才, 杨永耿, 李萍英. 减重对CHB和(或)NAFLD患者肝纤维化及脂肪肝程度的影响[J]. 肝脏, 2023, 28(2): 203-206.
[8]	刘是奕, 王点, 刘静, 唐栋, 陈公英. 非酒精性脂肪性肝炎药物临床试验合并症的管理[J]. 肝脏, 2023, 28(12): 1405-1407.
[9]	屠晓婷, 卜淑蕊. 短链脂肪酸在非酒精性脂肪性肝病和胰岛素抵抗中的作用及进展[J]. 肝脏, 2023, 28(12): 1521-1524.
[10]	刘希, 舒畅. 维生素D联合益生菌对肥胖儿童非酒精性脂肪肝的干预效果[J]. 肝脏, 2023, 28(11): 1351-1355.
[11]	朱雪晶, 王梦婷, 鄢和新, 黄仁杰. 慢性肝病常用动物模型及建模方案[J]. 肝脏, 2022, 27(9): 1030-1035.
[12]	宋叶雨, 范建高. 肌肉减少症与非酒精性脂肪性肝病共同的发病机制[J]. 肝脏, 2022, 27(4): 494-496.
[13]	王德鹤, 王怡群, 周盼, 叶敏超, 张玮, 李莹. 胰岛素增敏剂治疗非酒精性脂肪性肝炎的Meta分析[J]. 肝脏, 2022, 27(1): 98-102.
[14]	李静, 雷晓红, 茅益民. NFATc4在NASH领域的研究进展[J]. 肝脏, 2021, 26(9): 960-961.
[15]	吕晓玉, 王中京. 胰岛素抵抗的NAFLD患者外周血CD4⁺CD25⁺调节性T细胞的功能特征[J]. 肝脏, 2021, 26(6): 667-669.